What is cladribine?

What is Cladribine?

Cladribine (2-chlorodeoxyadenosine, 2-CdA) is a synthetic chlorinated purine nucleoside analog that acts as a potent antineoplastic and immunosuppressive agent, primarily used to treat hairy cell leukemia and relapsing forms of multiple sclerosis through selective lymphocyte depletion. 1

Mechanism of Action

Cladribine functions as a pro-drug requiring intracellular activation through phosphorylation. Its biological activity depends on preferential accumulation in cells with high ratios of deoxycytidine kinase to 5'-nucleotidases—particularly lymphocytes 2. Once phosphorylated, cladribine-phosphates:

• Interfere with DNA synthesis and repair by incorporating into DNA strands
• Inhibit critical enzymes including DNA polymerase and ribonucleotide reductase
• Cause DNA strand breaks leading to apoptosis in both resting and dividing cells 2

This mechanism produces targeted and sustained reduction of circulating T and B lymphocytes, which is therapeutically beneficial in autoimmune conditions like multiple sclerosis and in hematologic malignancies 2.

Clinical Applications

Hairy Cell Leukemia (Primary Indication)

Cladribine is recommended as first-line treatment for symptomatic hairy cell leukemia in young and fit patients 3. The drug demonstrates exceptional efficacy:

• Complete response rates of 85-91% after a single course 3
• Overall response rates of 87-100% 3
• Durable remissions without maintenance therapy 3

Administration regimens 4, 3:

• Continuous IV infusion: 0.09 mg/kg/day for 5-7 days
• 2-hour IV infusion: 0.12-0.14 mg/kg/day for 5-7 days
• Weekly IV: 0.12-0.15 mg/kg once weekly for 5-6 weeks
• Subcutaneous: 0.1-0.14 mg/kg/day for 5-7 days (does not require hospitalization)

All routes demonstrate similar efficacy, though subcutaneous administration offers greater convenience 3.

Multiple Sclerosis

Cladribine tablets function as an immune reconstitution therapy for relapsing forms of MS 5. The drug selectively depletes lymphocytes, followed by immune reconstitution with a different lymphocyte repertoire that provides durable disease control 5. Beyond peripheral immune effects, cladribine demonstrates good CNS penetration and can induce apoptosis of microglial cells while reducing pro-inflammatory cytokine production (IL-1β, IL-6, TNF-α) 6.

Other Hematologic Malignancies

Preliminary data support potential use in chronic lymphocytic leukemia, non-Hodgkin's lymphoma, and as part of conditioning regimens for allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia 7, 8.

Safety Profile and Monitoring

Major Toxicities

Myelosuppression is the dose-limiting toxicity 1. Expected hematologic nadirs in hairy cell leukemia patients:

• Platelet count reaches 100 × 10⁹/L by Day 12
• Absolute neutrophil count reaches 1,500 × 10⁶/L by Week 5
• Hemoglobin reaches 12 g/dL by Week 8 1

Fever occurs frequently (69% of patients), predominantly in neutropenic patients during the first month 1. Less than one-third of febrile events are associated with documented infection, but empiric antibiotics should be initiated as clinically indicated 1.

Critical Monitoring Requirements

Cladribine must be administered only under supervision of physicians experienced with cancer chemotherapeutic agents 1. Required monitoring includes:

• Peripheral blood counts: Particularly during first 4-8 weeks post-treatment to detect anemia, neutropenia, thrombocytopenia 1
• Renal and hepatic function: Especially in patients with underlying dysfunction 1
• Bone marrow evaluation: After peripheral counts normalize to confirm response 1

Important Precautions

• Exercise caution in patients with renal or hepatic insufficiency—acute renal insufficiency has been reported with high doses 1
• Carefully evaluate risk-benefit in patients with active infections given known myelosuppressive effects 1
• Rare cases of tumor lysis syndrome reported in patients with high tumor burden 1
• Must be diluted in designated IV solutions prior to administration 1
• Carcinogenic potential cannot be excluded based on demonstrated genotoxicity 1

Pharmaceutical Characteristics

Cladribine injection is supplied as a clear, colorless, sterile, preservative-free, isotonic solution containing 1 mg/mL in single-dose vials 1. The solution has pH 5.5-8.0 (adjusted to 6.3 ± 0.3) and contains 9 mg sodium chloride per mL 1.